Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22991642 | 0.82 | TTR (0.54) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL7927726 | 0.77 | GABRA1 (0.78) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL25836512 | 0.76 | TTR (0.34) | TTRGABRA1GABRB1GABRB2 | |
| SCHEMBL22991569 | 0.75 | TTR (0.61) | TTRGABRA1GABRB1GABRB2ERN1 | |
| Triiodophenol SCHEMBL338137 | 0.75 | TTR (1.00) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL21159415 | 0.74 | TTR (0.59) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL26696417 | 0.73 | TTR (0.58) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL10877649 | 0.72 | TTR (0.56) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL26295914 | 0.71 | TTR (0.54) | TTRGABRA1GABRB1GABRB2ERN1 | |
| SCHEMBL29228155 | 0.70 | CA1 (0.36) | GABRA1GABRB1GABRB2CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279172-A1 | RADIOPAQUE POLYMERS | Boston Scientific Medical Device Limited (IE) | 2023-09-07 | — | — | US | disclosed |
| US-11702498-B2 | Radiopaque polymers | BIOCOMPATIBLES UK LIMITED | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279172-A1 | RADIOPAQUE POLYMERS | SSTR3, VHL, PLG | TTR 1841/4885GABRA1 1869/4885GABRB1 2722/4885 |
| US-11702498-B2 | Radiopaque polymers | OXER1, NR5A1, AQP1 | TTR 3572/4885GABRA1 1985/4885GABRB1 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.